Clinical trials: Inhalation
Bronchiolitis
Inhaled Hypertonic Saline Use in the Emergency Department to Treat Acute Viral Bronchiolitis
Acute viral bronchiolitis is an extremely common childhood disease, responsible for approximately 17% of childhood admissions to hospital per year, with an annually cost that reaches U$ 500 million.
- Trial name
- NCT02045238
- Testing
- Hypertonic Saline, Chest X-Ray, Respiratory virus screening test
- Where
- Brazil
- Volunteers
- 32 people
- Sponsor
- University of Sao Paulo
Asthma
A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma
The primary objective is to compare the efficacy of Symbicort Single inhaler Therapy with treatment according to conventional best practice in adult patients with persistent asthma.
- Trial name
- PASSION (NCT00628758)
- Testing
- Symbicort TBH - Turbuhaler, beta-II-agonist, inhale steroid
- Where
- 15 sites in Turkey (Türkiye)
- Volunteers
- 430 people
- Sponsor
- AstraZeneca
Asthma
Inhaled Steroids at Discharge After Emergency Department Visits for Children With Uncontrolled Asthma
Many children have asthma and this causes problems with their health. A lot of children with uncontrolled asthma use emergency departments for asthma care, and so this is an ideal place for an intervention for these children.
- Trial name
- NCT01881412
- Testing
- fluticasone, Standard Asthma Discharge Instructions
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- Rhode Island Hospital
Schizophrenia
Staccato Loxapine Single Dose PK
The objective of this study was to assess the safety, tolerability and pharmacokinetics of a single inhaled dose of (administered in 1 or 2 puffs) Staccato Loxapine in healthy volunteers.
- Trial name
- NCT00444028
- Testing
- inhaled Loxapine 0.625 mg, inhaled Loxapine 1.25 mg, inhaled Loxapine 2.5 mg
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Alexza Pharmaceuticals, Inc.
Congenital Heart Disease, Single Ventricle
Improving Functional Capacity in Fontan Patients Through Inspiratory Muscle Training
Mechanisms that typically result in increased cardiac output, such as inotropic support, increased heart rate, and decreased afterload, have a blunted effect in Fontan circulation.
- Trial name
- NCT01977222
- Testing
- THRESHOLD(TM) INSPIRATORY MUSCLE TRAINER
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Boston Children's Hospital
Chronic Obstructive Pulmonary Disease - COPD
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
To assess the bronchodilation of three doses of formoterol fumarate (6 μg, 12 μg and 24 μg) twice daily (BID) administered via Pressair® compared to placebo and to open-label nebulized formoterol fumarate (20 μg and 40 μg).
- Trial name
- NCT02796651
- Testing
- Formoterol fumarate (6 μg), Formoterol furmarate (20 μg), Formoterol fumarate (12 μg)
- Where
- 20 sites in United States
- Volunteers
- 132 people
- Sponsor
- AstraZeneca
Amyotrophic Lateral Sclerosis (ALS), Neuromuscular Diseases
Acute Intermittent Hypoxia and Breathing in Neuromuscular Disease
This project seeks to investigate the effects of a single acute intermittent hypoxia (AIH) session on respiratory and non-respiratory motor function and EMG (electromyography) activity on patients with ALS (amyotrophic lateral…
- Trial name
- AIH-ALS (NCT03645031)
- Testing
- Acute Intermittent Hypoxia
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- University of Florida
Asthma
Impact of FeNO Measured With the NIOX MINO® Device in Identifying Asthma Among Patients With Prolonged Respiratory Symptoms
Overall Aim: To better understand the diagnostic process for prolonged respiratory events and determine the potential role of FeNO in assessing the possibility of asthma as the symptoms etiology.
- Trial name
- NCT01518322
- Testing
- NIOX MINO®
- Where
- 13 sites in United States
- Volunteers
- 235 people, healthy volunteers welcome
- Sponsor
- Aerocrine AB
Asthma
Efficacy and Safety of Indacaterol Acetate Delivered Via the Concept1 Inhalation Device in Children Greater or Equal to 6 and Less Than 12 Years of Age With Asthma
This study is designed to explore lung function effects of two doses of indacaterol acetate, 75 μg and 150 μg, in pediatric asthma patients 6-11 years old, and to compare the systemic exposure to indacaterol in plasma with…
- Trial name
- NCT02892019
- Testing
- Indacaterol acetate 75 μg, Indacaterol acetate 150 μg
- Where
- 29 sites in Belgium, Colombia and 9 more
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Cystic Fibrosis, Burkholderia Infections
Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection
The purpose of this research study was to determine if an experimental drug called Aztreonam for Inhalation Solution (AZLI) was safe and effective to treat Burkholderia lung infections in patients with cystic fibrosis (CF).
- Trial name
- NCT01059565
- Testing
- AZLI
- Where
- 35 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- Gilead Sciences
Asthma
To Investigate the Effects of Altering the Time of Day of Dosing (Morning or Evening) With Fluticasone Furoate 100 Micrograms Once Daily Administered Via a Dry Powder Inhaler in Subjects With Asthma
This study will investigate the effects of altering the time of day of dosing (morning or evening) with Fluticasone Furoate 100 (FF 100) micrograms (mcg) once daily administered via a dry powder inhaler (DPI) in subjects with…
- Trial name
- NCT01808339
- Testing
- Fluticasone Furoate (FF)
- Where
- Australia
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Asthma
Early Airway Response to Allergen in Asthmatics (MK-0000-176)
This study will assess the Early Airway Response (EAR) associated change in forced expiratory volume in one second (FEV1) and plasma 9α-11ß-PGF2 ('9P') after single dose pretreatment of nedocromil, montelukast, and mometasone.
- Trial name
- NCT01061333
- Testing
- Nedocromil, Comparator: Montelukast, Comparator: Mometasone
- Volunteers
- 16 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The Purpose of this study is to assess the efficacy and safety of two strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT01054885
- Testing
- FF Inhalation Powder, FF/GW642444 Inhalation Powder, GW642444 Inhalation Powder
- Where
- 149 sites in United States, Argentina and 7 more
- Volunteers
- 1,226 people
- Sponsor
- GlaxoSmithKline
Asthma
The Clinical Effect of Monodisperse Fluticasone Propionate in Asthma
The objective here is to determine that the efficiency of inhaled drug delivery can be improved by using a fine mist cloud of drug particles (as opposed to a coarse mist cloud of drug particles).
- Trial name
- NCT01662778
- Testing
- 1.5 microns at 50mg, 6 microns at 50mg, MDI FP
- Where
- 2 sites in United Kingdom
- Volunteers
- 21 people
- Sponsor
- Imperial College London
Lung Disease
DREAM: Does Inhaled Fluticasone REsult in Obstructive Sleep Apnea Manifestations?
This study is being conducted to find out if the use of inhaled corticosteroids has an affect on upper airway (UAW) collapsibility and sleep apnea risk.
- Trial name
- DREAM (NCT01184118)
- Testing
- FP 220 mcg 2 puffs BID
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Wisconsin, Madison
Cystic Fibrosis
Efficacy and Safety of 28 or 56 Day Treatment for Pseudomonas Aeruginosa in Children With Cystic Fibrosis
This study assessed time to recurrence of infection with Pseudomonas aeruginosa following treatment of the initial infection with tobramycin nebuliser solution.
- Trial name
- ELITE (NCT00391976)
- Testing
- Tobramycin solution for inhalation 300 mg
- Volunteers
- 123 people
- Sponsor
- Novartis
Sleep Apnea, Sleep Disordered Breathing
Sleepiness and the Effects of CPAP on Salivary Cortisol and Alpha-Amylase Levels in Patients With Sleep Apnea
Patients with Obstructive Sleep Apnea Syndrome (OSAS) will evidence higher levels of salivary cortisol and alpha-amylase levels prior to use of placebo and continuous positive airway pressure (CPAP) and will evidence a decrease…
- Trial name
- NCT01196117
- Testing
- 14 days of CPAP therapy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Medical College of Wisconsin
Pulmonary Disease, Chronic Obstructive
A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPD
The purpose of the study is to investigate the efficacy and safety of fluticasone furoate/vilanterol Inhalation Powder compared with placebo over a 24 weeks treatment period in subjects of Asian ancestry with Chronic Obstructive…
- Trial name
- NCT01376245
- Testing
- fluticasone furoate/vilanterol
- Where
- 34 sites in China, Philippines and 2 more
- Volunteers
- 646 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This will be a Phase IIIb multicentre, randomized, double-blind, double-dummy, 12-week parallel group study evaluating the effects of once daily in the morning treatment of FF/VI Inhalation Powder versus Fluticasone…
- Trial name
- NCT01706328
- Testing
- FF/VI 100/25 Inhalation Powder NDPI, Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS, Salbutamol as needed
- Where
- 63 sites in United States, Germany and 3 more
- Volunteers
- 828 people
- Sponsor
- GlaxoSmithKline
Nontuberculous Mycobacterium Infection
A Proof of Concept Study of Inhaled Nitric Oxide for Adults With Pulmonary Non-Tuberculous Mycobacterial Infection
The purpose of this study is to evaluate the efficacy and safety of open-label exposure of gNO in patients with NTM lung disease. Subjects will receive the study drug by inhaling through a nasal mask.
- Trial name
- NCT03748992
- Testing
- gNO
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Medical University of South Carolina